Expert CMC advice on quality dossier preparation in support of a Compassionate Use Program in France

6 Aug 2019

Catalog

Expert CMC advice on quality dossier preparation in support of a Compassionate Use Program in France

In the context of PRIME, a European biotechnological company entrusted BlueReg CMC team with the task of bringing the available quality data package of a synthetic peptide to global registration prerequisites for the next steps of development (the Compassionate use program in France, Phase III global program, registration in Europe and US) and to write the Quality part of the IMPD for early access submission in France.

Other content from BlueReg Group

Download

Catalog
PDF 586 kB